文献速递前列腺增生与排尿功能障碍

性腺功能减退对初次尿道成形术后手术结局的影响:基于大型多机构数据库的分析

The Impact of Hypogonadism on Surgical Outcomes Following Primary Urethroplasty: Analysis of a Large Multi-institutional Database.
PubMed 文献 · Urology · 2024-01-06

基于TriNetX 2008–2023年数据的回顾性队列研究,比较性腺功能正常与性腺功能减退(症状+睾酮<300 ng/dL)患者初次尿道成形术后的结局。倾向评分匹配后,性腺功能减退组5年再次尿道成形率显著更高(11% vs 6%,RR 1.5,95%CI 1.2–2.2,P=0.01),内镜修复率无差异;性腺功能减退患者中,术前接受睾酮替代治疗者5年再次尿道成形率显著高于未治疗者(15% vs 7%,RR 1.8,95%CI 1.1–3.3,P=0.02)。结论认为既存性腺功能减退可能对初次尿道成形术后手术结局有轻度不良影响。

要点

  • 性腺功能减退患者初次尿道成形术后5年再次尿道成形率显著高于性腺功能正常者(11% vs 6%,RR 1.5,P=0.01)。
  • 两组5年内镜修复率无显著差异(11% vs 11%,RR 1.0,95%CI 0.7–1.5,P=1.0)。
  • 性腺功能减退患者中,术前接受睾酮替代治疗者5年再次尿道成形率显著高于未治疗者(15% vs 7%,RR 1.8,P=0.02)。

核心结论

  • 基于大型回顾性队列数据,既存性腺功能减退可能对初次尿道成形术后手术结局有轻度不良影响。

研究设计与样本

  • 回顾性队列研究,使用TriNetX数据库纳入2008–2023年接受初次尿道成形术的患者。
  • 共识别性腺功能正常患者12,556例和性腺功能减退患者488例(其中睾酮替代治疗153例,未治疗335例)。
  • 尿道成形术中位年龄55岁,中位随访5年。
  • 采用倾向评分匹配调整合并症差异后,比较477例性腺功能正常患者与477例性腺功能减退患者。
  • 对性腺功能减退患者进行亚组分析,比较术前接受睾酮替代治疗与未治疗者。

主要发现

  • 倾向评分匹配后,性腺功能减退组5年再次尿道成形率显著高于性腺功能正常组(11% vs 6%,RR 1.5,95%CI 1.2–2.2,P=0.01)。
  • 两组5年内镜修复率无显著差异(11% vs 11%,RR 1.0,95%CI 0.7–1.5,P=1.0)。
  • 两组5年内镜修复或再次尿道成形无修订生存时间无差异。
  • 性腺功能减退患者中,术前接受睾酮替代治疗者5年再次尿道成形率显著高于未治疗者(15% vs 7%,RR 1.8,95%CI 1.1–3.3,P=0.02)。
  • 性腺功能减退亚组中,接受与未接受睾酮替代治疗者5年内镜修复率无显著差异(14% vs 10%,RR 1.3,95%CI 0.7–2.4,P=0.2)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare surgical outcomes among a cohort of eugonadal and hypogonadal patients undergoing primary urethroplasty (UP). METHODS: A retrospective cohort study was conducted using TriNetX between 2008-2023. Patients who were eugonadal and hypogonadal (symptoms plus testosterone <300 ng/dL) prior to UP were compared. A subgroup analysis of hypogonadal patients was performed to compare those with testosterone replacement therapy (TRT) vs TRT-naïve prior to UP. Propensity-score matching was used to adjust for differences in comorbidities. Outcomes were 5-year revision rates and revision-free survival for endoscopic revision and redo UP following primary UP. RESULTS: We identified 12,556 eugonadal and 488 hypogonadal patients (153 TRT+, 335 TRT-) undergoing UP. Median age at UP and follow-up was 55years and 5years, respectively. After propensity-score matching, we compared 477 eugonadal and 477 hypogonadal patients. Hypogonadal patients had a statistically significantly higher 5-year redo UP rate (11% vs 6%, relative risk [RR] 1.5 [95%CI, 1.2-2.2]; P = .01) when compared to eugonadal patients however there was no difference in 5-year rates of endoscopic revision (11% vs 11%, RR 1.0 [95%CI, 0.7-1.5]; P = 1.0). We observed no difference in 5-year revision-free survival time for endoscopic revision or redo UP between groups. Hypogonadal patients treated with TRT had a significantly higher 5-year redo UP rate (15% vs 7%, RR 1.8 [95%CI, 1.1-3.3]; P = .02) compared to hypogonadal patients that were TRT-naïve prior to UP. There was no difference in rates of endoscopic revision (14% vs 10%, RR 1.3 [95%CI, 0.7-2.4]; P = .2) between subgroups. CONCLUSION: Pre-existing hypogonadism may modestly adversely affect surgical outcomes following primary UP based on data from a large, retrospective cohort study.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Gabrielson AT, Galansky L, Shneyderman M, et al. The Impact of Hypogonadism on Surgical Outcomes Following Primary Urethroplasty: Analysis of a Large Multi-institutional Database. Urology. 2024. PMID: 38190864. doi:10.1016/j.urology.2023.12.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。